| Primary |
| Attention Deficit/hyperactivity Disorder |
68.1% |
| Aggression |
4.3% |
| Anxiety |
4.3% |
| Hypertension |
4.3% |
| Vitamin Supplementation |
4.3% |
| Anger |
2.1% |
| Headache |
2.1% |
| Product Used For Unknown Indication |
2.1% |
| Psychomotor Hyperactivity |
2.1% |
| Sleep Disorder |
2.1% |
| Tic |
2.1% |
| Tourette's Disorder |
2.1% |
|
| Suicidal Ideation |
13.8% |
| Syncope |
13.8% |
| Orthostatic Hypotension |
6.9% |
| Product Quality Issue |
6.9% |
| Vomiting |
6.9% |
| Aggression |
3.4% |
| Anxiety |
3.4% |
| Drug Prescribing Error |
3.4% |
| Dysphoria |
3.4% |
| Ileus Paralytic |
3.4% |
| Pressure Of Speech |
3.4% |
| Sedation |
3.4% |
| Skin Nodule |
3.4% |
| Somnolence |
3.4% |
| Therapeutic Response Unexpected With Drug Substitution |
3.4% |
| Therapy Cessation |
3.4% |
| Tinnitus |
3.4% |
| Urticaria |
3.4% |
| Vasculitis |
3.4% |
| Vision Blurred |
3.4% |
|
| Secondary |
| Attention Deficit/hyperactivity Disorder |
35.5% |
| Headache |
12.1% |
| Drug Use For Unknown Indication |
9.7% |
| Self Injurious Behaviour |
8.9% |
| Asperger's Disorder |
5.6% |
| Suicide Attempt |
4.8% |
| Aggression |
4.0% |
| Affective Disorder |
3.2% |
| Vitamin Supplementation |
3.2% |
| Product Used For Unknown Indication |
2.4% |
| Anxiety |
1.6% |
| Autism |
1.6% |
| Hypertension |
1.6% |
| Appetite Disorder |
0.8% |
| Bipolar Disorder |
0.8% |
| Hypervolaemia |
0.8% |
| Psychomotor Hyperactivity |
0.8% |
| Tic |
0.8% |
| Tuberous Sclerosis |
0.8% |
| Urine Output Decreased |
0.8% |
|
| Headache |
19.6% |
| Suicidal Ideation |
13.0% |
| Syncope |
8.7% |
| Completed Suicide |
6.5% |
| Urticaria |
6.5% |
| Abnormal Behaviour |
4.3% |
| Dysphoria |
4.3% |
| Idiopathic Thrombocytopenic Purpura |
4.3% |
| Somnolence |
4.3% |
| Weight Decreased |
4.3% |
| Withdrawal Hypertension |
4.3% |
| Aggression |
2.2% |
| Agitation |
2.2% |
| Anxiety |
2.2% |
| Drug Dispensing Error |
2.2% |
| Drug Ineffective |
2.2% |
| Drug Toxicity |
2.2% |
| Fear |
2.2% |
| Hypotension |
2.2% |
| Nephrotic Syndrome |
2.2% |
|
| Concomitant |
| Hypertension |
20.5% |
| Attention Deficit/hyperactivity Disorder |
10.1% |
| Drug Use For Unknown Indication |
8.2% |
| Product Used For Unknown Indication |
7.0% |
| Bipolar Disorder |
6.1% |
| Laryngospasm |
5.7% |
| Anxiety |
4.4% |
| Insomnia |
4.2% |
| Multiple Sclerosis |
3.8% |
| Rheumatoid Arthritis |
3.8% |
| Gastrooesophageal Reflux Disease |
3.6% |
| Pain |
3.4% |
| Affective Disorder |
2.5% |
| Back Pain |
2.5% |
| Convulsion |
2.5% |
| Mental Status Changes |
2.5% |
| Bipolar I Disorder |
2.3% |
| Depression |
2.3% |
| Prophylaxis |
2.3% |
| Obsessive-compulsive Disorder |
2.1% |
|
| Weight Increased |
15.4% |
| Progressive Multifocal Leukoencephalopathy |
9.9% |
| Tremor |
7.7% |
| Vomiting |
6.6% |
| Product Quality Issue |
5.5% |
| Sepsis |
5.5% |
| Convulsion |
4.4% |
| Nausea |
4.4% |
| Pain |
4.4% |
| Tardive Dyskinesia |
4.4% |
| Blood Pressure Increased |
3.3% |
| Hyperkalaemia |
3.3% |
| Insomnia |
3.3% |
| No Adverse Event |
3.3% |
| Renal Failure Acute |
3.3% |
| Subdural Haematoma |
3.3% |
| Torticollis |
3.3% |
| Type 2 Diabetes Mellitus |
3.3% |
| Urinary Tract Infection |
3.3% |
| Abnormal Behaviour |
2.2% |
|
| Interacting |
| Attention Deficit/hyperactivity Disorder |
50.0% |
| Depression |
50.0% |
|
| Inappropriate Schedule Of Drug Administration |
100.0% |
|
